The ESC 2024 guidelines recognize the growing evidence supporting the use of SGLT2 inhibitors in hypertensive patients with coexisting conditions such as chronic kidney disease, type 2 diabetes mellitus, and heart failure. The gene discussed is SLC5A2; the disease is heart failure.